FDA allows expanded use of Bristol Myers' cell therapy for blood cancer

The U.S. Food and Drug Administration on Friday allowed the use of cell therapy Abecma from Bristol-Myers Squibb (BMY.N)  and 2seventybio (TSVT.O) in less severely affected patients with a type of blood cancer.